Medications for B-Cell Lymphoma
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in B-Cell Lymphoma.
Found 7 Approved Drugs for B-Cell Lymphoma
RiTUXimab
Brand Names
Rituxan, Ruxience, Riabni, Rituxan Hycela, Truxima
RiTUXimab
Brand Names
Rituxan, Ruxience, Riabni, Rituxan Hycela, Truxima
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: November 26, 1997
Classification: CD20-directed Cytolytic Antibody
RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL).
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Pembrolizumab
Brand Names
Keytruda QLEX, Keytruda
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 15, 2015
Classification: Programmed Death Receptor-1 Blocking Antibody
KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with unresectable or metastatic melanoma.
Adcetris
Generic Name
Brentuximab Vedotin
Adcetris
Generic Name
Brentuximab Vedotin
Form: Injection
Method of administration: Intravenous
FDA approval date: August 25, 2011
Classification: CD30-directed Immunoconjugate
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Columvi
Generic Name
Glofitamab
Columvi
Generic Name
Glofitamab
Form: Concentrate, Solution
Method of administration: Intravenous
FDA approval date: June 15, 2023
Classification: Bispecific CD20-directed CD3 T Cell Engager
COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (1.
Zynlonta
Generic Name
Loncastuximab Tesirine
Zynlonta
Generic Name
Loncastuximab Tesirine
Form: Injection
Method of administration: Intravenous
FDA approval date: April 30, 2021
ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (1.
Showing 1-5 of 7
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances